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Abstract 
 
Background 
Targeted deep sequencing is a highly effective technology to identify known and novel single 
nucleotide variants (SNVs) with many applications in translational medicine, disease 
monitoring and cancer profiling. However, identification of SNVs using deep sequencing data 
is a challenging computational problem as different sequencing artifacts limit the analytical 
sensitivity of SNV detection, especially at low variant allele frequencies (VAFs).  
Methods 
To address the problem of relatively high noise levels in amplicon-based deep sequencing 
data (e.g. with the Ion AmpliSeq technology) in the context of SNV calling, we have 
developed a new bioinformatics tool called AmpliSolve. AmpliSolve uses a set of normal 
samples to model position-specific, strand-specific and nucleotide-specific background 
artifacts (noise), and deploys a Poisson model-based statistical framework for SNV detection.  
Results 
Our tests on both synthetic and real data indicate that AmpliSolve achieves a good trade-off 
between precision and sensitivity, even at VAF below 5% and as low as 1%. We further 
validate AmpliSolve by applying it to the detection of SNVs in 96 circulating tumor DNA 
samples at three clinically relevant genomic positions and compare the results to digital 
droplet PCR experiments.  
Conclusions 
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AmpliSolve is a new tool for in-silico estimation of background noise and for detection of 
low frequency SNVs in targeted deep sequencing data. Although AmpliSolve has been 
specifically designed for and tested on amplicon-based libraries sequenced with the Ion 
Torrent platform it can, in principle, be applied to other sequencing platforms as well. 
AmpliSolve is freely available at https://github.com/dkleftogi/AmpliSolve.   
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Background 
 
Targeted next-generation sequencing (NGS) is a powerful technology to identify known and 
novel variants in selected genomic regions of interest [1]. It allows achieving high coverage 
levels (i.e., higher than 1000x) and, in principle, to confidently identify variants even when 
they occur at low allele frequencies. This is particularly important in cancer research and has 
many clinical applications, e.g. in relation to disease management. Typically, tumors are 
heterogeneous consisting of multiple clones and sub-clones the relative abundance of which 
can change over time depending on several factors, including treatment [2]. Identification of 
low frequency mutations is clinically relevant, among other reasons, for early diagnosis, 
disease monitoring and timely detection of the emergence of resistance clones under 
treatment [3]. 
 
Over the past years, it has been established that cancer patients’ circulating free DNA 
(cfDNA) contains tumor-derived DNA fragments (ctDNA) that can be used as an alternative 
to solid biopsies in clinical settings [4]. However, identifying cancer-specific mutations in 
liquid biopsy samples is challenging, as the relative proportion of ctDNA in cfDNA can be 
low, especially at cancer’s early stages. There are also several sources of sequencing errors 
including PCR artifacts, often reaching up to 1% Variant Allele Frequency (VAF), that 
reduce further the analytical sensitivity for detecting cancer-associated mutations [4]. Error 
correction techniques can be incorporated into NGS assays enabling ultra-sensitive single 
nucleotide variant (SNV) detection (VAF ~ 0.1%) but at a significant extra cost [5,6]. Thus, 
there is a need to reliably detect SNVs in more conventional deep sequencing data.  
 
In-silico identification of SNVs from NGS data is a well-studied problem [7,8]. However, the 
majority of existing variant calling programs have been designed for whole-exome and 
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whole-genome experiments sequenced at coverage of approximately 30x to 100x. At the 
same time, available variant calling software for targeted deep sequencing experiments have 
been typically developed for and tested on Illumina data [9].  
 
Compared to Illumina, Ion Torrent sequencing has a higher per base error rate and an 
associated lower accuracy in identifying mutations [10, 11]. However, it has the advantage of 
requiring lower amounts of input DNA and it offers both reduced cost and turnaround time. 
Thus, it is a cost-effective strategy for screening large cohorts of patients and it is particularly 
suited for point-of-care clinical applications [1], for example in conjunction with the Ion 
AmpliSeq Cancer Hotspot Panel. Given its translational potential, there is a real need to 
improve the variant calling workflow and recently a number of methods have been developed 
to deal specifically with Ion Torrent data [12, 13, 14].  
 
Here we introduce AmpliSolve, a new bioinformatics method to detect SNVs in targeted deep 
sequencing data. It combines in-silico background error estimation with statistical modeling 
and it is particularly suited to deal with data of comparatively high noise levels, similar to the 
ones produced by the Ion AmpliSeq library preparation. In order to estimate background 
noise levels per position, strand and nucleotide substitution, AmpliSolve takes as input deep-
sequencing data from a set of normal samples. This information is then fed to a Poisson 
model for the identification of SNVs. Experimental results using normal samples (self-
consistency test), synthetic variants and clinical data sequenced with a custom Ion AmpliSeq 
gene panel, demonstrate that AmpliSolve achieves a good trade-off between precision and 
sensitivity, even for VAF values below 5% and as low as 1%.  
Methods 
 
Method overview 
 
AmpliSolve consists of two main programs written in C++: AmpliSolveErrorEstimation and 
AmpliSolveVariantCalling. AmpliSolveErrorEstimation requires the availability of a set of 
normal samples processed with the deep sequencing platform and panel of choice. Here, we 
focus on the Ion Torrent Personal Genome Machine (PGM) and a custom AmpliSeq panel, a 
technology known to have relatively high rates of sequencing error compared to others. The 
program uses the normal samples to infer position-specific, nucleotide specific and strand-
specific background sequencing error levels (noise) across the targeted regions. Execution of 
AmpliSolveErrorEstimation is performed only once per panel design. Error estimates are then 
used as input to the AmpliSolveVariantCalling program for SNVs’ detection. The procedures 
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for in-silico noise estimation and SNV identification are described below. In Figure 1 we 
present a graphical overview of the AmpliSolve computational workflow.  
 
In-silico identification of the background sequencing error  
 
Our strategy for estimating background error levels, implemented in the 
AmpliSolveErrorEstimation program, is based on the assumption that alternative alleles 
observed at VAF<5% in normal samples are, in the majority of cases, the result of sequencing 
errors (see Figure S1 for the distribution of non-reference allele frequencies in normal 
samples showing the separation between heterozygous germline variants and lower frequency 
‘noise’ variants). Accordingly, we utilize a set of normal samples to estimate background 
noise in our custom panel. Notably, we estimate error levels separately for each genomic 
position, each nucleotide (alternative allele) and each of the two (forward and reverse) 
strands. In particular, for each genomic position we generate six error estimates (i.e. two each 
for the three alternative alleles). Error estimates are fed to a Poisson model, which is then 
used to calculate the p-value of the observed substitutions representing true variants versus 
them being noise. The detailed implementation is as follows. We first extract “raw” counts for 
each position, alternative allele and strand from the BAM files [15] of a set of N normal 
samples using the ASEQ software [16]. We run ASEQ with the quality parameters suggested 
by the authors of a previous study based on Ion AmpliSeq data [17], namely: minimum base 
quality  = 20, minimum read quality = 20 and minimum read coverage = 20. At every 
genomic position, we estimate the background error s separately for each alternative allele α 
and strand (+ or -) by calculating the fraction of reads carrying the alternative allele on a 
given strand across all normal samples. More specifically we use the following formula:  
 𝑠!,!/! = !"!,!/!!"#!/! + 𝐶                               (1) 
with  
 𝐸𝑟!,!/! = 𝑅!!,!/!!!!!    (1a) 
    
and  
 𝐸𝑟𝑑!/! = 𝑅𝐷!!/!!!!!              (1b) 
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We denote with Riα,+ and Riα,- the number of reads supporting the alternative allele α on the 
forward and reverse strand, respectively, in normal sample i. We denote with RDi+ and RDi- 
the total number of reads (read depth) at the genomic position of interest on the forward and 
reverse strand, respectively, in normal sample i. Summations are taken over all normal 
samples utilized for the error estimation. C in equation (1) is a constant pseudo-count 
parameter that is introduced to mitigate the problem of positions in which the alternative 
allele read count might be underestimated (e.g. due to a relatively low read depth at a given 
position in the normal samples). In the Results section we test values of C in the range from 
10-5 to 2!10-2.  
 
When calculating the summations in (1a) and (1b), we apply two filters that aim to increase 
the quality of the error estimation at specific positions and for specific alternative alleles α at 
that position. First, at a given position, samples for which an alternative allele α has VAF > 
5% are not considered at that position for that particular allele. This is because a frequency 
greater than 5% is likely to indicate, in that sample, either the presence of a real variant (i.e. a 
single nucleotide polymorphism) or a particularly noisy ‘read-out’. Second, samples that at a 
given position have coverage lower than a predefined threshold either on the forward or on 
the reverse strand are not considered for computing 𝐸𝑟!,!/!  (1a) and 𝐸𝑟𝑑!/! (1b) for any 
allele α at that position. In the following we use a threshold of 100 reads which, in our case, 
typically excludes 5% of sites per sample (see Figure S2); however, this parameter can be 
adjusted depending on the study design. After applying these filters, positions and alternative 
alleles for which 2/3 or more of the normal samples cannot be used for calculating the 
summations in (1a) and (1b) are considered non-callable. We note that among non-callable 
cases there may be positions with alleles that are either frequent in the population or simply 
over-represented in the specific set of normal samples used for the error estimation. However, 
given that AmpliSolve main goal is the identification of somatic mutations this does not 
constitute a major limitation. 
 
SNV detection using a cumulative Poisson distribution 
 
Given a sample of interest, for every alternative allele α featuring a non-zero strand-specific 
(+ or –) variant read count 𝑘!,!/!, the	 AmpliSolveVariantCalling program uses a Poisson 
model to calculate the probability that 𝑘!,!/!  or more variant reads are produced by 
sequencing errors, i.e. the p-value. Only positions that, in the sample of interest, have read 
depth on each strand higher than a pre-assigned threshold RDmin are considered (in the 
following, we set RDmin = 100 unless otherwise specified). At these positions, the calculated 
p-value is a function of the normal sample-based sequencing error 𝑠!,!/! from the previous 
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section and of both the number of variant reads 𝑘!,!/! and the strand-specific read depth K+/- 
in the sample of interest (K+/- >RDmin ). In particular: 
 𝑝 − 𝑣𝑎𝑙𝑢𝑒 𝑣𝑎𝑟𝑖𝑎𝑛𝑡  𝑘!,!/!,𝐾!/!, 𝑠!,!/!) = 1 −  𝑒!!∗! (!∗!)!!!!!!!!!      (2) 
 
   
Where, for better readability, on the right side of the equation we have omitted all α symbols 
for k and s, as well as, +/- symbols for k, K and s. We observe that K*s is the expected 
number of random substitutions for a depth of coverage K or the mean of the Poisson 
distribution. Note that p-values are not corrected for multiple testing. The strand-specific p-
values are finally converted to quality scores using the formula Q=-10*log10(p-value). In its 
output, for all positions in the panel carrying substitutions with Q score equal to or greater 
than 5 on both strands, AmpliSolve reports the average Q score between the two strands. Vice 
versa, positions with no substitutions or with substitutions with associated Q score lower than 
5 on one or both strands are not reported in AmpliSolve’s output. All reported SNVs are 
further tested for and potentially assigned one or more of the following warning flags:  
a) ‘LowQ’ if the Q score is lower than 20 in at least one of the two strands.  
b) ‘LowSupportingReads’ if the SNV is supported by less than 5 reads per strand in the 
tumor samples being analysed.  
c) ‘AmpliconEdge’ if the SNV is located within overlapping amplicon edge regions, 
which may result in sequencing artifacts.  
d) ‘StrandBias’ if the SNV is associated to a strand-bias. We apply Fisher’s exact test to 
each SNV under the null hypothesis that the number of forward and reverse reads 
supporting the variant should be proportional to the total number of reads sequenced 
in the forward and reverse strands, respectively. The flag is assigned to substitutions 
for which the p-value of the Fisher’s exact test is lower than a pre-defined value SBth. 
In the following we set SBth = 0.05 (unless otherwise specified).   
e) ‘HomoPolymerRegion’ if the SNV is located within a homopolymer region using the 
same criteria as in [18]. 
f) ‘PositionWithHighNoise’ if the SNV is supported by more than 5 reads per strand but 
the associated VAF is lower than the maximum VAF at this position across all 
normal samples in the training set. 
 
If no warning is issued, AmpliSolve assigns a ‘PASS’ flag to the SNV.   
 
Performance measures 
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To assess AmpliSolve’s success in detecting SNVs, we use a number of performance metrics: 
1. Sensitivity or True Positive Rate (TPR) = TP / (TP+FN) 
2. Precision or Positive Predictive Value (PPV)= TP/(TP+FP) 
3. False Discovery Rate (FDR) = 1-PPV=FP / (FP+TP) 
4. Harmonic mean of Precision and Sensitivity (F1) = 2*TP / (2*TP +FP + FN) 
Where, TP is the number of True Positive predictions, FN is the number of False Negative 
predictions and FP is the number of False Positive predictions.  
 
Clinical data used in this study 
 
For the development and evaluation of AmpliSolve, we have access to an extensive collection 
of clinical samples from castration-resistant prostate cancer (CRPC) patients, part of which 
had been already presented in previous publications [17,19,20,21]. The collection comprises 
184 germline samples (white blood cells, buccal swabs or saliva) and more than 450 liquid 
biopsy plasma samples (note that for some patients there are multiple liquid biopsies and a 
small minority of liquid biopsy samples has no matched normal). In practice for this study, 
we rely on all 184 normal samples but only use 96 liquid biopsy samples for which results 
from digital droplet PCR (ddPCR) assays are available (see below). For 5 additional patients 
we have access to 10 solid tumor samples from metastatic sites (1, 2 and 3 samples from 
respectively 1, 3 and 1 patients) and their associated 5 germline samples. For the available 
samples, we have the following data: 
a) For all samples (germlines, liquid biopsies and solid tumors), we have Ion Torrent 
sequencing data obtained using a custom Ion AmpliSeq panel of 367 amplicons spanning 
40,814 genomic positions at around 1000-1500x coverage. The panel targets both intronic and 
exonic regions in chromosomes 8, 10, 14, 17, 21 and X including commonly aberrated genes 
such as PTEN, CYP17A1, FOXA1, TP53, SPOP as well as the androgen receptor (AR) gene, 
which is one of the main drivers of CRPC, and the drug target CYP17A1. More details about 
the sequencing protocol, data processing and additional information about the application of 
our custom Ion AmpliSeq panel in CRPC diagnostic studies can be found in [17] and [19]. 
These papers also include a description of a variant caller that we used as starting point for 
developing AmpliSolve.  We call variants in these Ion AmpliSeq data with our program 
AmpliSolve.  
 
b) For the 10 solid tumor samples and 5 matched germline samples, in addition to Ion Torrent 
data, we have Illumina Whole Genome Sequencing (WGS) data at around 80-100x (tumor) 
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and 30x (germline) coverage.  We call variants in WGS data according to a previously 
established pipeline [22], which we describe in the next section.  
 
c) For 96 liquid biopsy samples, we have results from ddPCR assays to screen 3 clinically 
relevant SNVs in the AR gene. These SNVs have been linked to resistance to targeted therapy 
in CRPC patients, namely: 2105T>A (p.L702H), 2226G->T (p.W742C) and 2632A>G 
(p.T878A). ddPCR in the plasma samples was performed using 2-4 ng of DNA, using Life 
Technologies Custom Taqman snp genotyping assay (product codes AH0JFRC, 
C_175239649_10 and C_175239651_10, respectively). Following droplet generation 
(AutoDg, Bio-Rad) and PCR, samples were run on the Bio-Rad QX200 droplet reader and 
analyzed using the QuantaSoft software. 
 
WGS variant calling pipeline 
 
We used Illumina WGS data to generate a benchmark set of calls (“ground-truth”) against 
which AmpliSolve performance is evaluated. WGS data have been processed using standard 
tools, such as Skewer [23] for adapter trimming, BWA-MEM [24] for mapping and Picard 
[25] for duplicate removal. In order to call SNVs we run a previously developed pipeline [22] 
that utilizes jointly Mutect [26] and Platypus [18] (throughout the manuscript this pipeline is 
denoted as MutPlat). Briefly, we first run Mutect (default parameters) on each paired tumor-
normal samples. Then, we use Mutect’s calls as priors for Platypus and jointly call variants on 
all tumors and matched normal samples of a patient (further details are provided in Additional 
file 1: Supplementary Methods). Our ground-truth set of calls consists of both germline and 
somatic mutations extracted as explained below.  
 
Germline variants are identified as those variants called in the normal (GT=0/1 or 1/1) and 
that, additionally, have either a PASS filter flag or don’t have a PASS filter flag (could have 
e.g. ‘badReads’) but are present in 1000 genomes (phase 3 release) [27]. For AmpliSolve 
validation purposes we consider only tumor samples but include both germline and somatic 
SNVs. By including germline SNVs, in particular, we are able to test a higher number of low 
VAF mutations than would be possible when considering only somatic mutations. This is due 
to a combination of somatic deletions and germline DNA contamination in the tumor 
samples. Indeed, while somatic deletions cause loss of some germline SNPs in tumor DNA, 
germline DNA contamination (i.e. <100% tumor purity) means that these mutations may still 
be present in the tumor samples, albeit with a lower VAF. Note that if somatic deletions occur 
in high tumor purity samples and/or the sequencing coverage is not deep enough, germline 
variants may have no supporting read at all in the WGS tumor data. We keep also these 
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limiting cases as part of our ground-truth set of variants as they might be (and sometimes are) 
detectable in the targeted Ion AmpliSeq data. 
 
To call a somatic SNV we require all of the following criteria to be met: i) Platypus filter: 
PASS, alleleBias, Q20, QD, SC or HapScore, ii) at least 3 reads supporting the variant in the 
tumor, iii) at least 10 reads covering the position in the germline and no support for the 
variant in the germline (NV=0 and genotype GT= 0/0), iv) SNV not present in the 1000 
genomes database. 
 
SNV callers tested for comparison 
 
On WGS and ctDNA samples, we compare AmpliSolve to SiNVICT [12], a tool that has 
been shown to be effective in detecting mutations at very low VAF in Ion Torrent data. We 
run SiNVICT (version 1.0) with default parameters and with no additional data pre-
processing steps. We split the tumor samples (10 metastatic solid tumors plus 96 ctDNA 
samples) into 3 batches of similar size and we run SiNVICT simultaneously on all samples 
from each batch.    SiNVICT applies a number of post-processing filters and calls variants at 
6 different confidence levels, with level 6 assigned to variants that pass all filters. On ctDNA 
samples, we additionally compare AmpliSolve to deepSNV [9], a state-of-the-art method for 
calling low allele frequency variants in deep sequencing data (although originally designed to 
detect sub-clonal mutations on Illumina rather than Ion AmpliSeq data). We run deepSNV 
(version 1.21.3) with default parameters following the available vignette in the R package. 
 
How to run AmpliSolve 
 
AmpliSolve two modules, AmpliSolveErrorEstimation	and	AmpliSolveVariantCalling, can 
be downloaded from github (https://github.com/dkleftogi/AmpliSolve). Additional 
requirements include running versions of the programs Samtools [15], ASEQ [16] and the 
Boost libraries for C++. Here we provide a brief description of how to run AmpliSolve, 
however, more detailed information and a number of examples are available on the github 
page.  
 
For a given amplicon panel, error estimation at each genomic position, for each alternative 
nucleotide and for each of the two strands requires availability of amplicon-based data from N 
normal sample files. Although we don’t enforce a minimum value for N, values below 10 are 
likely to give low-quality error estimations. In general, we suggest using as many normal 
samples as possible when training the error matrix for your panel. If normal samples are not 
available, AmpliSolveErrorEstimation assigns a constant error rate to all positions, 
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nucleotides and strands in the panel. The default constant error is 0.01 but the user can specify 
a different value if needed (e.g. for different sequencing platforms). Note that AmpliSolveErrorEstimation	 does	 not	 take	 bam	 files	 as	 input	 but	 rather	 bam-derived	read	count files. Read count files can be obtained by running the program ASEQ [16].  Once 
the read count files have been produced, the user needs to set the value of the C pseudo-count 
parameter (equation (1)). The choice of C will depend on the trade-off between precision and 
sensitivity the user is interested in. Users can refer to the benchmarking experiments 
performed in this paper. In general, values of C between 0.001 and 0.01 should suit most 
applications.   	
Once the error matrix has been calculated, it can be fed to the AmpliSolveVariantCalling 
program together with read count files for the tumor samples again to be produced by running 
ASEQ. Note that AmpliSolveVariantCalling does not require matched normal-tumor samples 
for calling SNVs. In fact, AmpliSolveVariantCalling calls all variants it can find in the tumor 
sample, including germline variants. To separate germline from somatic variants users will 
need to run AmpliSolveVariantCalling on a matched normal sample and take the difference 
between the two output files. Command-line syntax for running AmpliSolveErrorEstimation 
and AmpliSolveVariantCalling is provided on github.  
Results  
Sequencing error estimation, self-consistency test and AmpliSolve FDR  
AmpliSolve estimates the background sequencing noise by analyzing the distribution of 
alternative alleles in normal samples. As previously reported, PGM errors tend to be 
systematic [11]. For example, we observe that A>G (T>C) and, to a lesser extent, C>T (G>A) 
mutations tend to have a higher background error level (see Figure S3). For this reason, 
AmpliSolve assigns separate error levels to each genomic position, each alternative allele and 
each strand (see Figure S4). These are then utilized to build the Poisson models that are at the 
core of AmpliSolve SNV calling (Methods). In this section, we study AmpliSolve variant 
calling performance as a function of two parameters: the pseudo-count C (equation (1) in 
Methods) and the number of normal samples N that are used to calculate the error estimations. 
We perform a self-consistency test using sets of normal samples to train our models and 
other, non-overlapping sets of normal samples for testing them. Given a dataset of N=184 
normal samples (Methods), we proceed as follows: 1) we select a number M < N of samples 
at random and additionally a value c of the C parameter; 2) we use the M samples to train our 
Poisson-models with C=c; 3) we use the models obtained in 2) to predict SNVs in the 
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remaining N-M samples; 4) we calculate FDR and TPR by defining as negatives all 
alternative alleles that have VAF<20% and as positives those for which VAF≥20%. This 
threshold is chosen empirically based on the distributions of VAFs that we observe in the data 
(Figure S1); 5) we repeat steps 1) to 4) 50 times for each pair of (M,c) values, each time 
selecting a new set of M samples at random; 6) we calculate median FDR and TPR over the 
50 experiments. We perform steps 1) to 6) for all combinations of the following values of M 
(size of the training set) and c (parameter C): M=10, 20, 40, 80, 120 and c=10-5, 5*10-5, 10-4, 
5*10-4, 10-3, 2*10-3, 5*10-3, 10-2, 2*10-2. In Figure 2a and 2b, we plot the median FDR for 
each size of the training set (10-120) as a function of C; additionally, for comparison, we plot 
the median FDR of a method in which we skip the error estimation step and we set instead 
s=c for all positions, nucleotides and strands (‘baseline caller’) (see equation (1) in Methods 
for the definition of s). The FDR reported in Figure 2a is calculated by considering an SNV as 
called by AmpliSolve if and only if it has a Q score higher or equal 20 (i.e. p-value ≤ 0.01; 
this is equivalent to the SNV not having a LowQ flag, see Methods). The FDR reported in 
Figure 2b, instead, is calculated by considering an SNV as called by AmpliSolve if and only 
if the program assigns a ‘PASS’ flag to it, that is, if none of the warnings described in the 
Methods section applies. In Figure 2a we see that, for relatively small values of c, the training 
set size N affects the method performance, with more samples providing better error 
estimation and thus lower FDR. Also, our approach provides an approximately 2- to 4-fold 
FDR improvement over the baseline caller at all values of c≤0.01. For values of c>0.01, 
instead, differences with the baseline caller become negligible. Figure 2b shows that filtering 
AmpliSolve’s SNV calls using the warning flags that we define on top of LowQ (such as 
those related to low number of supporting reads, homopolymer regions, etc.) has the effect of 
further improving the FDR. Also, it reduces differences between FDRs obtained when using 
training sets of different size. All of the above findings suggest that estimating the 
background noise at each position, for each nucleotide and for each strand is important for 
reducing the number of FPs arising from noise in Ion AmpliSeq data. If we now consider the 
median values of the Sensitivity measure (or TPR), we discover that in all our experiments 
they are close to 1, irrespective of the value of M and c. This close to perfect Sensitivity is not 
surprising as our definition of positives (VAF≥20%) makes them relatively simple to 
discriminate from the background noise especially considering the fact that most of them 
have VAFs that are much higher than 20% (Figure S1). Thus, in order to truly test 
AmpliSolve Sensitivity, we have to perform a different kind of experiment, which we 
describe in the next section.  
Synthetic variants test for TPR estimation 
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In order to test the sensitivity of our method at low VAFs (0.5% to 4%), we design the 
following experiment. We first select two amplicons on the AR gene (1,017 genomic 
positions overall); the AR gene is chosen because clinically relevant but for this purpose other 
choices would be equally valid. Then, we use 120 normal samples randomly selected from the 
full set of 184 described in Methods to estimate the errors at each position in the two 
amplicons, for each nucleotide and each strand, according to formula (1). Next, we test the 
method’s sensitivity on synthetic variants. For each possible alternative allele at each of the 
1,017 amplicon positions, we set read depth to a fixed value COV and the number of reads 
supporting the allele to 2a (a supporting reads on the forward strand and a on the reverse 
strand). We use COV=800, 1600, 3200, 6400 (values in this range apply to more than 60% of 
full panel positions with coverage >200, see Figure S5) and for each value of COV we select 
a corresponding to VAFs of 0.5%, 1%, 1.25%, 2%, 3% and 4%. For example for COV=800 
we test a=2,4,5,8,12,16. We then apply the Poisson models previously trained on the 120 
normal samples to predict variants at each position and for each alternative allele and consider 
only AmpliSolve calls with a ‘PASS’ quality flag. We consider all synthetic variants to be 
positives (thus, no FDR can be calculated in this case) and ask how many of these can be 
detected by AmpliSolve. We stress that while in each experiment the VAF is by design the 
same at all positions and for each alternative allele and strand, following estimation from the 
normal samples the error estimate is position-, alternative allele- and strand-dependent. We 
calculate the TPR for all combinations of COV and VAF. We do this for several values of the 
pseudo-count parameter C in the range of low AmpliSolve FDR as calculated from the self-
consistency test in the previous section or the range of main interest for applications 
(C=0.001, 0.002, 0.005, 0.01, 0.02, see Figure 2b).  
Figures 3(a-e) highlight the role of the C parameter as an approximate lower bound for 
AmpliSolve sensitivity (see equation (1)). Typically, AmpliSolve identifies few or no variants 
at allele frequencies equal to or lower than C, in the range of tested coverage depth (see, in 
particular, Figures 3c-e). For example, for C=0.005 no calls are made at VAF=0.5% even at 
values of COV as high a 6,400. Along the same lines, for values of C equal 0.01 and 0.02, 
which correspond to FDRs below 1.6% and 0.6%, respectively (Figure 2b), the lowest VAFs 
that AmpliSolve can detect are above 1% and 2%, respectively. For VAF values above C, on 
the other hand, sensitivity grows quickly with increasing VAF. For example within the depth 
of coverage range that we have analyzed, when using C=0.01 and C=0.02 AmpliSolve 
successfully calls the vast majority of synthetic variants at VAF 2% and 3%, respectively. 
When we compare the Sensitivity histograms in Figures 3a-e to the FDR curves in Figure 2b, 
we see that AmpliSolve can reliably predict synthetic SNVs at VAFs as low as 1% while still 
in a regime of relatively low FDR. Indeed for C=0.002, at an estimated FDR of 6.8% (Figure 
	 13	
2b), AmpliSolve calls most SNVs with 1% allele frequency at depth of coverage >1,600 and 
most SNVs with allele frequency 0.5% at depth of coverage >3,200. While it will be up to the 
user to select the best trade-off between FDR and TPR for a specific experiment, it would 
appear that values of C between 0.001 and 0.01 would likely represent a reasonable 
compromise between these two performance measures in most applications.  
Benchmarking AmpliSolve perfomance using Illumina WGS data 
For 5 additional CRPC patients, we have access to 10 metastatic solid tumor (for some 
patients more than one metastasis) and associated normal samples. These were sequenced 
both with our custom Ion AmpliSeq panel and with the Illumina platform as WGS (the latter, 
with average coverage ~100X) (Methods). We use these 10 samples to provide a validation of 
AmpliSolve SNV calls in a more realistic set-up with respect to what shown in the previous 
two sections. For training our AmpliSolve Poisson models, we use the full set of 184 normal 
samples sequenced with the Ion AmpliSeq technology and we set C=0.002. 
In the solid tumor samples, when run on the Ion AmpliSeq data AmpliSolve identifies a total 
of 556 SNVs. For the same set of genomic positions processed by AmpliSolve, our WGS-
variant calling pipeline MutPlat (Methods) calls a total of 603 SNVs in the corresponding 
Illumina data. The list of positions processed by AmpliSolve includes all those covered by 
our amplicon panel minus the ones for which no background error estimate can be produced 
(Methods). Almost all SNVs identified in the WGS data are germline (592 out of 603) but 
some of them have low VAF in the tumor samples because of deletions and loss of 
heterozygosity (LOH) events in the tumor DNA combined with germline DNA 
contamination. It is therefore a very valuable test set that includes confidently identified 
variants at low VAF. 
The level of agreement between AmpliSolve and the ground-truth set of calls from MutPlat is 
summarized in Figure 4a and in Table 1. On this data, AmpliSolve achieves 87% TPR, 94% 
PPV and 90% F1. In particular, of the 556 SNVs called by AmpliSolve, 525 SNVs are also 
identified by MutPlat (TP). The remaining 31 are likely false positives (FP) although some of 
them might be real somatic variants with very low VAFs (and hence non detectable by a 
WGS done at 100x). The 78 SNVs additionally identified by MutPlat in the WGS data are 
likely AmpliSolve false negatives (FP). However, we note that 48 of them correspond to 
positions not called because the coverage in the tumor samples was below the threshold of 
100 reads per strand and 26 were filtered out because of the strandBias flag. By simply setting 
more lenient parameters RDmin=50 and SBth=0.01 we are able to drastically reduce the 
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number of missed calls without affecting AmpliSolve precision. With these settings we obtain 
571 TP, 34 FP and 32 FN, which translates into 95% TPR, 94% PPV and 94% F1.  
In Figure 4b and 4c we report a scatter plot of the VAFs in the WGS and AmpliSeq data with 
colors indicating common calls (purple), MutPlat-only calls (green) and AmpliSolve-only 
calls (blue), respectively. Overall there is a good concordance between AmpliSolve and 
MutPlat calls, even at low VAF (Figure 4c). In particular, AmpliSolve correctly identifies 18 
out of 21 SNVs with VAF < 5% in the WGS calls. AmpliSolve does call a number of likely 
false positives at low VAF, however we note that most of them occur at recurrent positions 
across patients and could therefore potentially be identified and discarded at a post variant 
calling analysis stage.  
In Table 1, we additionally compare AmpliSolve’s performance to the one of SiNVICT when 
run on the same 10 solid tumor samples.(MutPlat calls on the Illumina data are used as 
ground truth in both cases). SiNVICT assigns a confidence level (1 to 6) to its calls according 
to a series of hierarchical filters (each filter eliminates some calls from the previous level). On 
our dataset, SINVICT’s highest confidence level (level 6) although very precise appears to 
miss a substantial number of SNVs (i.e. it has low sensitivity), especially at low VAF. Better 
overall results are obtained at confidence levels 3 and 4, In this case, precision and sensitivity 
values are similar to the ones obtained by Amplisolve when using RDmin=50 and SBth=0.01. 
Interestingly, at low VAF AmpliSolve and SiNVICT seem to identify slightly different sets of 
SNVs, suggesting that it might be possible to improve SNV calling by appropriately 
combining them.   
Clinical application using ctDNA samples and ddPCR for validation 
One of the most promising clinical applications of ctDNA is profiling of specific mutations 
associated with tumor progression and resistance to cancer therapies. To evaluate 
AmpliSolve’s usefulness for this important task, we use results from a ddPCR screen on 96 
samples from our CRPC patients at three genomic positions within the AR gene, which are 
associated with resistance to targeted therapy (Methods). ddPCR detects 30 variants in total at 
these positions in a VAF range of 0.1 to 49% (note, however, that in some experiments only 
the presence or absence of the variant was recorded). Next, we compare AmpliSolve calls at 
the same positions in the AmpliSeq NGS data for the same samples (predictions made after 
training AmpliSolve with pseudo-count parameter C=0.002 on 184 normal samples). In 
Figure 5a we summarize the level of agreement between AmpliSolve and the ddPCR 
experiments. AmpliSolve correctly calls 19 out of 30 ddPCR variants and predicts variants at 
two additional positions. If we take the ddPCR experiments as our ground-truth, this 
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translates into 90% PPV 63% TPR and 74% F1 for AmpliSolve at these 3 clinically relevant 
genomic positions.  
As a comparison, we run the SiNVICT and deepSNV methods on the same Ion Torrent data 
and extract their SNV calls at these positions. The results are summarized in Table 2. Similar 
to what observed in the previous section, SiNVICT highest confidence levels (5 and 6) have 
low sensitivity (30% TPR). Better results are obtained at lower confidence level (1 to 4) 
whereby SiNVICT correctly identifies 17 out of 30 ddPCR variants without introducing any 
false positives. In total deepSNV calls 18 SNVs, 15 of which are correct.   
When looking at AmpliSolve predictions in more details (Figure 5b), we note that all ddPCR 
positives not called by our program (and additionally missed by both SiNVICT and 
deepSNV) have VAF<1% in the NGS data and that AmpliSolve succeeds in calling all 
ddPCR positives at higher NGS frequencies including several at VAFs between 1% and 5%. 
It is also important to note that AmpliSolve correctly predicts 256 out of 258 (99.2%) ddPCR 
negatives. While the results presented in this section refer to only three genomic positions, 
they are indicative of AmpliSolve’s potential value in a clinically relevant setting.  
	
Discussion 
 
In this study we present AmpliSolve, a new bioinformatics method that combines position-
specific, nucleotide-specific and strand-specific background error estimation with statistical 
modeling for SNV detection in amplicon-based deep sequencing data. AmpliSolve is 
originally designed for the Ion AmpliSeq platform that is affected by higher error levels 
compared to, for example, Illumina platforms. Our method is based on the estimation of noise 
levels from normal samples and uses a Poisson model to calculate the p-value of the detected 
variant. We assess AmpliSolve’s performance with experiments that use normal samples 
(self-consistency tests) and simulated data (synthetic variants) and, additionally, with tests 
that utilize real metastatic samples sequenced with both Ion Torrent and Illumina platforms. 
In these experiments, AmpliSolve achieves a good balance between precision and sensitivity, 
even at VAF < 5%. These experiments also suggest possible ways to further improve the 
method, such as adopting a better strand bias filter, reducing the minimum coverage 
requirement for calling a variant and introducing a ‘black list’ of positions characterized by an 
unusual noise distribution across samples (e.g. bimodal). Further, we test AmpliSolve in a 
clinically relevant setting by calling SNVs in 96 liquid biopsy samples at 3 positions that had 
been additionally screened by ddPCR assay. In this experiment AmpliSolve successfully 
identifies SNVs at VAF as low as 1% in the NGS data. This opens up interesting possibilities 
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for clinical applications using the Ion Torrent PGM such as, for example, tracking mutations 
in ctDNA to monitor treatment effectiveness and/or disease relapse.  
 
Conclusions 
AmpliSolve is a new computational tool for the detection of low frequency SNVs in targeted 
deep sequencing data. It uses a set of germline samples to build a sequencing error profile at 
each genomic position of interest. Based on these profiles AmpliSolve estimates the 
likelihood of a variant being real or just the result of sequencing artefacts. We test 
AmpliSolve on clinical cancer samples sequenced with a custom Ion AmpliSeq gene panel 
and show that AmpliSolve can correctly identify variants even at allele frequency below 5% 
and as low as 1%. This is significant because detecting variants with low allele frequency can 
be challenging using Ion Torrent sequencing. From a methodological point of view, we 
believe that the use of models with position-specific error estimates, as described here, could 
have a significant impact on variant detection for other sequencing platforms as well.   
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Additional file 1: Supplementary Methods. Details of the MutPlat pipeline. 
 
Additional file 2: Figure S1. Variant allele frequency (VAF) distributions for the A, T, C, G 
nucleotides as calculated from 30 randomly chosen normal samples across our custom 
AmpliSeq panel. Only VAFs < 60% are displayed. The red lines mark VAF = 20%. 
 
Additional file 3: Figure S2. Fraction of sites in a normal sample sequenced at a given 
coverage or more across our custom AmpliSeq panel.  The values are calculated over 30 
randomly selected samples.  
 
Additional file 4: Figure S3. Distributions of background error values by mutation type. 
Panels (a), (b), (c) and (d) refers to mutations from reference allele A, C, G and T 
respectively. Mutations are split by alternative allele and strand, (+) and (-). Note the higher 
error values for A>G (T>C) and C>T (G>A) mutations. Plots are bound to error values of 
0.005 on the y-axis for visual clarity.     
 
Additional file 5: Figure S4. Position-specific, allele-specific and strand-specific frequency of 
alternative alleles in 100 consecutive positions in the AR gene. 
 
Additional file 6: Figure S5. Fraction of sites in our custom AmpliSeq panel sequenced at a 
given coverage or more. The values are calculated over 30 randomly selected ctDNA 
samples. Note that positions with depth of coverage less than 200 are not considered for 
calculating the total number of positions.  The red lines represent the upper and lower bounds 
of coverage used in the synthetic variant test. 
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Figures 
 
Figure 1 
 
 
 
Graphical representation of AmpliSolve’s workflow for estimating the noise levels and detecting SNVs. The 
workflow comprises the following steps: a) Screening the available normal samples to identify reads supporting 
alleles other than the reference. b) Error estimation per position, per nucleotide and per strand for all positions in 
the gene panel based on the distribution of alternative allele counts in (a); only alternative counts corresponding to 
VAF<5% are taken into consideration; c) For each genomic position in a tumor sample, the method identifies the 
total coverage of the position and the number of reads supporting the alternative alleles, if any. d) Given the 
information from steps b) and c) the method applies a Poisson distribution-based model to compute the p-value 
that the variant (red line) is real. This p-value is then transformed to a quality score that is used by AmpliSolve 
together with additional quality criteria to identify SNVs.    
 
Figure 2 
 
 
 
Assessing AmpliSolve’s performance using normal samples. a) Median AmpliSolve FDR (%) as a function of 
the model pseudo-count parameter, when using different numbers M of normal samples as training set and testing 
on the remaining normal samples. We consider as TP all normal variants with VAF≥20% and as FP all normal 
variants with VAF<20% (see Text). We consider all AmpliSolve calls that have Q-score≥20. b) Same as (a) when 
considering only AmpliSolve calls with a ‘PASS’ quality flag (see Text). 
	 22	
 
 
Figure 3 
 
 
Assessing AmpliSolve’s sensitivity using synthetic data. (a-e) AmpliSolve TPR (Sensitivity) values in in-silico 
synthetic variant experiments. We test different combinations of VAF, depth of coverage and C parameter values 
(see Text).  
 
Figure 4 
 
 
Benchmarking AmpliSolve calls with Illumina WGS calls a) Venn diagram of mutations on 10 samples 
sequenced with both Ion Torrent and Illumina platforms and called respectively by AmpliSolve and by MutPlat. 
Low coverage positions denote mutations excluded by AmpliSolve because poorly covered (<100 reads on at least 
one strand, ‘uncallable’ by AmpliSolve). (b) Scatter plot of VAFs in WGS and AmpliSeq data. Note that all the 
SNVs not called by AmpliSolve (green point) have some support in the data and are reported in its output (hence 
they have AF > 0) but are filtered out, mostly because of strand bias. (c) Same as (b) but for VAFs<20%. Note that 
some concordant calls (purple points) have WGS AF=0; these are real germline variants with no support in the 
tumor (Methods). For the sake of this comparison, both in (b) and in (c) we don’t consider the 49 mutations at 
positions of low coverage in Ion Ampliseq data  (see (a)) (‘uncallable’ for AmpliSolve).  
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Figure 5 
 
 
 
Validating AmpliSolve performance with ddPCR experiments. a) Venn diagram of mutations in 96 samples at 
3 positions as determined by AmpliSolve and ddPCR experiments. False positives refer to variants called by 
AmpliSolve and not detected by ddPCR, false negatives the opposite. In 256 out of 288 cases neither AmpliSolve 
nor ddPCR detect a mutation. (b) Scatter plot of the VAFs in the ddPCR and Ion Torrent data. Most of the SNVs 
missed by AmpliSolve (green points) have some support in the NGS data but they cannot be distinguished from 
noise. Because of the log scale, we arbitrarily set AF=10-4 for negative calls with AF=0. Similarly, we set AF=1 for 
ddPCR calls for which no allele frequency information is available.  
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Table 1.  
 
Comparison between AmpliSolve and SiNVICT calls across the targeted panel. MutPlat 
calls on Illumina WGS data have been used as ground-truth. SiNVICT levels correspond to 
confidence levels in the calls (6 being the highest). TP=True Positives, FP=False Positives, 
FN= False Negatives, TPR=True Positives Rate (Sensitivity), PPV=Positive Predictive Value 
(Precision), F1=Harmonic mean of Precision and Sensitivity.     
 
 
  TP FP FN TPR PPV F1 
AmpliSolve  525 31 78 87% 94% 90% 
 
 
 
SiNVICT 
Level 1 591 156 12 98% 79% 88% 
Level 2 587 154 16 97% 79% 87% 
Level 3 575 34 28 95% 94% 95% 
Level 4 575 34 28 95% 94% 95% 
Level 5 141 12 457 24% 92% 38% 
Level 6 104 3 494 17% 97% 29% 							
Table 2 
 
Comparison of SNV calling on 96 samples at 3 genomics positions.  The 3 positions on the 
AR gene were screened by ddPCR used here as ground-truth. SINVICT Levels 5 and 6 and 
Levels 1, 2, 3 and 4 have been grouped as they give the same results. TP=True Positives, 
FP=False Positives, FN= False Negatives, TPR=True Positives Rate (Sensitivity), 
PPV=Positive Predictive Value (Precision), F1=Harmonic mean of Precision and Sensitivity.        	
  TP FP FN TPR PPV F1 
AmpliSolve  19 2 11 63% 90% 74% 
SiNVICT 
Levels 1,2,3,4 17 0 13 57% 100% 73% 
Levels 5,6 9 0 21 30% 100% 46% 
deepSNV  15 3 15 50% 83% 62% 	
